MoFo News Item

Morrison & Foerster Secures FDA Emergency Use Authorization for BGI Genomics

The quick test detects novel coronavirus with a three hour turnaround

27 Mar 2020

Morrison & Foerster secured an Emergency Use Authorization (EUA) from the U.S. Food Drug Administration (FDA) for client BGI Genomics for its Real-Time SARS-CoV-2 Test in under two weeks.

BGI’s Real-Time SARS-CoV-2 Test detects novel coronavirus with high sensitivity and a three hour turnaround time. The EUA allows the test to be available in the United States immediately for high-volume testing capabilities and to quickly diagnose patients.

In addition to this authorization being vital to serving the public health during the global COVID-19 pandemic, it is the first-ever FDA approval received by BGI Genomics.

The MoFo team advising BGI Genomics on this matter included FDA partner Bethany Hills and Financial Services partner Jiang Liu; and associates Anthony Parenti, Keunbong Do, and Hilary Hoffman; and scientific analyst Liz Newman.

Read the related press release.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.